Dosages
To treat carcinoma of the prostate, usual adult dose for prostate cancer include:
- 6 mg or 10.8 mg subcutaneously into the upper abdominal wall once
- The 3.6 mg dosage may be repeated every 28 days
- The 10.8 mg dosage may be repeated every 12 weeks
- Intended for long-term administration unless clinically inappropriate
Prostate cancer, stage B2 to C (together with an antiandrogen and radiotherapy, start 8 weeks prior to radiotherapy):
Males:
Combination 28-day/12-week implant: 3.6 mg implant, followed in 28 days by 10.8 mg implant; or 28-day implant (alternate dosing): 3.6 mg; repeated every 28 days for a total of 4 doses (2 depots preceding and 2 during radiotherapy)
Uses:
- It can be used together with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate. Treatment should begin 8 weeks prior to radiation therapy and continue during radiation.
- For palliative treatment of advanced carcinoma of the prostate.